FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068380087> ?p ?o ?g. }

• W2068380087 endingPage "1644" @default.
• W2068380087 startingPage "1637" @default.
• W2068380087 abstract "ObjectiveTo assess the effects of raloxifene on the ovaries, uterus, and serum hormone levels in premenopausal women.DesignProspective study comparing pretreatment findings with findings for those on treatment.SettingGovernment research hospital.Patient(s)Thirty women 35 to 47 years of age who were at high risk of breast cancer and had regular, ovulatory menstrual cycles.Intervention(s)Raloxifene (60 mg) and calcium (1,200 mg) daily for 2 years.Main Outcome Measure(s)Sonographic evidence of ovarian stimulation (≥2 corpora lutea, or follicular cysts of >2 cm, or single follicular cyst of >3 cm). Changes in endometrial thickness, fibroid size, hormone levels, and menstrual-cycle length.Result(s)Fifteen subjects developed some cycles with asymptomatic ovarian stimulation, and 9 developed benign endometrial polyps, compared with 2 subjects and 1 subject pretreatment, respectively. Uterine fibroid size was unchanged during raloxifene use in 16 subjects with fibroids. On treatment, E2 levels increased significantly only during the follicular phase, with peak E2 levels significantly higher in cycles showing ovarian stimulation compared with those without. Sex hormone–binding globulin increased, but levels of LH, FSH, P, DHEAS, and T did not. Endometrial thickness and cycle length were unchanged.Conclusion(s)Premenopausal subjects receiving raloxifene showed sonographic and hormonal evidence of ovarian stimulation. Endometrial thickness, cycle length, and fibroid size were unchanged. Benign asymptomatic endometrial polyps developed in some. To assess the effects of raloxifene on the ovaries, uterus, and serum hormone levels in premenopausal women. Prospective study comparing pretreatment findings with findings for those on treatment. Government research hospital. Thirty women 35 to 47 years of age who were at high risk of breast cancer and had regular, ovulatory menstrual cycles. Raloxifene (60 mg) and calcium (1,200 mg) daily for 2 years. Sonographic evidence of ovarian stimulation (≥2 corpora lutea, or follicular cysts of >2 cm, or single follicular cyst of >3 cm). Changes in endometrial thickness, fibroid size, hormone levels, and menstrual-cycle length. Fifteen subjects developed some cycles with asymptomatic ovarian stimulation, and 9 developed benign endometrial polyps, compared with 2 subjects and 1 subject pretreatment, respectively. Uterine fibroid size was unchanged during raloxifene use in 16 subjects with fibroids. On treatment, E2 levels increased significantly only during the follicular phase, with peak E2 levels significantly higher in cycles showing ovarian stimulation compared with those without. Sex hormone–binding globulin increased, but levels of LH, FSH, P, DHEAS, and T did not. Endometrial thickness and cycle length were unchanged. Premenopausal subjects receiving raloxifene showed sonographic and hormonal evidence of ovarian stimulation. Endometrial thickness, cycle length, and fibroid size were unchanged. Benign asymptomatic endometrial polyps developed in some." @default.
• W2068380087 created "2016-06-24" @default.
• W2068380087 creator A5013262825 @default.
• W2068380087 creator A5013971369 @default.
• W2068380087 creator A5024024043 @default.
• W2068380087 creator A5063766744 @default.
• W2068380087 creator A5068951391 @default.
• W2068380087 creator A5070905626 @default.
• W2068380087 creator A5075181478 @default.
• W2068380087 creator A5082089356 @default.
• W2068380087 creator A5085607161 @default.
• W2068380087 date "2007-12-01" @default.
• W2068380087 modified "2023-10-16" @default.
• W2068380087 title "Gynecologic and hormonal effects of raloxifene in premenopausal women" @default.
• W2068380087 cites W175660244 @default.
• W2068380087 cites W1965740586 @default.
• W2068380087 cites W1976264294 @default.
• W2068380087 cites W19931880 @default.
• W2068380087 cites W1997883187 @default.
• W2068380087 cites W2002816846 @default.
• W2068380087 cites W2003019536 @default.
• W2068380087 cites W2006931559 @default.
• W2068380087 cites W2018735824 @default.
• W2068380087 cites W2029278810 @default.
• W2068380087 cites W2036755428 @default.
• W2068380087 cites W2038976801 @default.
• W2068380087 cites W2040720403 @default.
• W2068380087 cites W2042688555 @default.
• W2068380087 cites W2049555849 @default.
• W2068380087 cites W2051176515 @default.
• W2068380087 cites W2051512330 @default.
• W2068380087 cites W2061948111 @default.
• W2068380087 cites W2065022554 @default.
• W2068380087 cites W2078542557 @default.
• W2068380087 cites W2085792714 @default.
• W2068380087 cites W2088437188 @default.
• W2068380087 cites W2094948761 @default.
• W2068380087 cites W2095354180 @default.
• W2068380087 cites W2112212344 @default.
• W2068380087 cites W2113137003 @default.
• W2068380087 cites W2122254445 @default.
• W2068380087 cites W2131942601 @default.
• W2068380087 cites W2134945901 @default.
• W2068380087 cites W2137603964 @default.
• W2068380087 cites W2145024831 @default.
• W2068380087 cites W2149165585 @default.
• W2068380087 cites W2164285221 @default.
• W2068380087 cites W2166969772 @default.
• W2068380087 cites W2181506022 @default.
• W2068380087 cites W4238359466 @default.
• W2068380087 cites W4254895480 @default.
• W2068380087 doi "https://doi.org/10.1016/j.fertnstert.2007.01.095" @default.
• W2068380087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17662283" @default.
• W2068380087 hasPublicationYear "2007" @default.
• W2068380087 type Work @default.
• W2068380087 sameAs 2068380087 @default.
• W2068380087 citedByCount "21" @default.
• W2068380087 countsByYear W20683800872012 @default.
• W2068380087 countsByYear W20683800872013 @default.
• W2068380087 countsByYear W20683800872014 @default.
• W2068380087 countsByYear W20683800872015 @default.
• W2068380087 countsByYear W20683800872016 @default.
• W2068380087 countsByYear W20683800872017 @default.
• W2068380087 countsByYear W20683800872018 @default.
• W2068380087 crossrefType "journal-article" @default.
• W2068380087 hasAuthorship W2068380087A5013262825 @default.
• W2068380087 hasAuthorship W2068380087A5013971369 @default.
• W2068380087 hasAuthorship W2068380087A5024024043 @default.
• W2068380087 hasAuthorship W2068380087A5063766744 @default.
• W2068380087 hasAuthorship W2068380087A5068951391 @default.
• W2068380087 hasAuthorship W2068380087A5070905626 @default.
• W2068380087 hasAuthorship W2068380087A5075181478 @default.
• W2068380087 hasAuthorship W2068380087A5082089356 @default.
• W2068380087 hasAuthorship W2068380087A5085607161 @default.
• W2068380087 hasBestOaLocation W20683800871 @default.
• W2068380087 hasConcept C121608353 @default.
• W2068380087 hasConcept C126322002 @default.
• W2068380087 hasConcept C134018914 @default.
• W2068380087 hasConcept C187785154 @default.
• W2068380087 hasConcept C2777176818 @default.
• W2068380087 hasConcept C2779058012 @default.
• W2068380087 hasConcept C2779066055 @default.
• W2068380087 hasConcept C2779889926 @default.
• W2068380087 hasConcept C2780566971 @default.
• W2068380087 hasConcept C29456083 @default.
• W2068380087 hasConcept C530470458 @default.
• W2068380087 hasConcept C71315377 @default.
• W2068380087 hasConcept C71924100 @default.
• W2068380087 hasConceptScore W2068380087C121608353 @default.
• W2068380087 hasConceptScore W2068380087C126322002 @default.
• W2068380087 hasConceptScore W2068380087C134018914 @default.
• W2068380087 hasConceptScore W2068380087C187785154 @default.
• W2068380087 hasConceptScore W2068380087C2777176818 @default.
• W2068380087 hasConceptScore W2068380087C2779058012 @default.
• W2068380087 hasConceptScore W2068380087C2779066055 @default.
• W2068380087 hasConceptScore W2068380087C2779889926 @default.
• W2068380087 hasConceptScore W2068380087C2780566971 @default.
• W2068380087 hasConceptScore W2068380087C29456083 @default.

• next